- Home
- SUPV vs FLGT Comparison
SUPV vs FLGT Comparison
Compare SUPV & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SUPV | FLGT |
|---|---|---|
| Founded | 1887 | 2011 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 814.9M | 867.4M |
| IPO Year | 2015 | 2016 |
Fundamental Metrics
Financial Performance| Metric | SUPV | FLGT |
|---|---|---|
| Price | $8.37 | $14.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | $13.00 | ★ $28.33 |
| AVG Volume (30 Days) | ★ 1.0M | 524.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.26% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,730,000.00 |
| Revenue This Year | $12.63 | $10.66 |
| Revenue Next Year | $43.89 | $12.17 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.54 | $13.46 |
| 52 Week High | $17.02 | $31.04 |
Technical Indicators
Market Signals| Indicator | SUPV | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 31.94 | 21.19 |
| Support Level | $4.71 | N/A |
| Resistance Level | $11.76 | $19.96 |
| Average True Range (ATR) | 0.62 | 0.93 |
| MACD | -0.19 | -0.69 |
| Stochastic Oscillator | 16.02 | 9.96 |
Price Performance
Historical ComparisonAbout SUPV Grupo Supervielle S.A. each Representing five Class B shares
Grupo Supervielle SA offers financial products & services. The company's segments include Personal and Business Banking, Corporate Banking, Bank Treasury, Consumer Finance, Insurance, and Asset Management and other services. The company provides services to individuals, small businesses, middle-market companies, and large corporates in Argentina. The company also offers mutual fund services.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.